Study of prognostic prediction in stage III and IV gastric carcinoma by immunological evaluation

免疫学评估对III、IV期胃癌预后的预测研究

• 批准号: 16591286
• 负责人: SATO Yuji
• 金额: $ 2.18万
• 依托单位: HOKKAIDO UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16591286/
• 关键词: MHC-class I; immunohistochemistry; gastric cancer; scirrhous type; frozen specimen; paraffin-embeded specimen; deletion of MHC-class I; cytokine; MHC分子; 免疫能; 腫瘍特異抗原; リンパ球表面抗原; frozen speimen

Study of prognostic prediction in stage III and IV gastric carcinoma by immunological evaluation.We investigated the immunological responses of fifty-four gastric carcinomas (GCs) by immunohistochemical staining. The stages were 12 patients for I,6 for II,7 for III,29 for IV. Formalin-fixed, paraffin-embeded tissues resected in the operation were sectioned at 4 μm, and they were stained with antibodies against HLA-class I, HLA-class II beta-2-microglobulin, MAGE-1,Lck,CD3,CD4 and CD8. The expression was designed as positive when stained over 10% in the field.The positive rate in the carcinoma cells was 84.3% for HLA- class I, 60.4% for beta-2 microglobulin and 38.0% for HLA-class II. And that of MAGE-1 and Lck was 11.3 and 3.7%, respectively. That in the T lymphocytes was 100% for CD3,96.2% for CD4,49.1% for CD8. But, there were no correlations between these factors and the stages of cancer. And also the factors did not correlate the prognoses of patients. These results showed that peptide-specific immunotherapy by HLA-class I-restricted cytotoxic T lymphocytes and others may not be effective for the GC patients of HLA-class I deletion.

免疫学评价对Ⅲ、Ⅳ期胃癌预后预测的研究采用免疫组化染色法对54例胃癌患者的免疫反应进行了研究。I期12例，II期6例，III期7例，IV期29例。将术中切除的福尔马林固定、石蜡包埋的组织切成4 μm的切片，并用抗HLA-I类、HLA-II类β-2-微球蛋白、法师-1、Lck、CD 3、CD 4和CD 8的抗体进行染色。在癌细胞中，HLA-Ⅰ类、β_2微球蛋白和HLA-Ⅱ类的阳性率分别为84.3%、60.4%和38.0%。法师1和Lck的阳性率分别为11.3%和3.7%。T淋巴细胞CD 3、CD 4、CD 8阳性率分别为100%、96.2%、49.1%。但是，这些因素与癌症的分期之间没有相关性。而且这些因素与患者的预后也无相关性。这些结果表明，肽特异性免疫治疗HLA-Ⅰ类限制性细胞毒性T淋巴细胞和其他可能是无效的HLA-Ⅰ类缺失的GC患者。

项目成果

Humoral Response to peptide correlate with over all survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.

基于预先存在的肽特异性细胞反应，对肽的体液反应与接种肽的晚期癌症患者的总体存活率相关。

• 发表时间: 2004
• 期刊: Clinical Cancer Research 10(3)
• 作者: Mine T;Sato Y;Noguchi M;Sasatomi T;Gouhara R;Tsuda N;Tanaka S;Shoumura H;Katagiri K;Rikimaru T;Shichijo S;Kamura T;Hashimoto T;Shirouzu K;Yamada A;Todo S;Itoh K;Yamana H
• 通讯作者: Yamana H

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

• DOI: 10.1158/1078-0432.ccr-05-2425
• 发表时间: 2006-06-01
• 期刊: CLINICAL CANCER RESEARCH
• 影响因子: 11.5
• 作者: Yoshida, Kazuhiro;Ninomiya, Motoki;Nishiyama, Masahiko
• 通讯作者: Nishiyama, Masahiko

Chemotheapy Prediction in esophageal cell carcinoma : Novel marker genes and efficacy-prediction formulae using expression data.

食管细胞癌的化疗预测：使用表达数据的新型标记基因和疗效预测公式。

• 发表时间: 2006
• 期刊: Int J Oncol 28
• 作者: Shimokuni T;Tanimoto K;Hiyama K;Otani K;Ohtaki M;Hihara J;Yoshida K;Noguchi T;Kawahara K;Natsugoe S;Aikou T;Okazaki Y;Hayashizaki Y;Sato Y;Todo S;Hiyama E;Nishiyama M
• 通讯作者: Nishiyama M

Phase II study of Docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. 2006, in press

多西紫杉醇和S-1联合治疗晚期或复发性胃癌的II期研究。

• 发表时间: 2006
• 期刊: Clin, Cancer Res In press
• 作者: Yoshida K;Ninomiya M;Takakura N;Hirabayashi N;Takiyama W;Sato Y;Todo S;Terashima M;Goto M;Sakamoto J;Nishiyama M
• 通讯作者: Nishiyama M

squamous cell carcinoma antigen- reactive CTLs in HLA-A24+ cancer patient.

HLA-A24 癌症患者的鳞状细胞癌抗原反应性 CTL。

• 发表时间: 2006
• 期刊: International J Oncol. In press
• 作者: Honnma S;Harada M;Yano H;Ogasawara S;Shichijo S;Matsueda S;Komatau N;Shomura H;Maeda Y;Sato Y;Todo S;Itoh K : Indentification of
• 通讯作者: Itoh K : Indentification of